Zenas's strong balance sheet, with $301.6M in cash and runway into late 2026, supports aggressive late-stage pipeline ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...

Revolution Medicines, Inc. ($RVMD) announced an update on their ongoing clinical study. Study Overview Revolution Medicines, Inc. is running a ...

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...

SE stock is rated Hold due to valuation constraints and pipeline setbacks, despite strong commercial execution with VYVGART.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Use of alternative endpoints in phase 3 oncology trials ...

Research into clinical uses for psychedelics has proliferated in recent years, but despite the constant stream of "psychedelic renaissance" news, the vast majority of studies remain in early, ...

While the third act of Avengers: Endgame could make this the most entertaining of the third Phase alone, this entry in The ...

Eddie Possehl is a dynamic and driven writer/director with a passion for the written word and all things film, television, comics, and games. His passion for storytelling led him to establish his own ...